WVE - Wave Life Sciences Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
20.57
-0.45 (-2.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close21.02
Open20.87
Bid20.54 x 1100
Ask20.57 x 800
Day's Range20.01 - 21.09
52 Week Range17.59 - 50.98
Volume105,648
Avg. Volume226,447
Market Cap705.152M
Beta (3Y Monthly)0.98
PE Ratio (TTM)N/A
EPS (TTM)-5.14
Earnings DateJul 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.67
Trade prices are not sourced from all markets
  • Are Insiders Selling Wave Life Sciences Ltd. (NASDAQ:WVE) Stock?
    Simply Wall St.

    Are Insiders Selling Wave Life Sciences Ltd. (NASDAQ:WVE) Stock?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • GlobeNewswire

    Wave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen

    CAMBRIDGE, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) --  Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to suvodirsen for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to exon 51 skipping. The designation was based on comprehensive in vitro and in vivo nonclinical data that support the potential for suvodirsen to address a significant unmet medical need.

  • GlobeNewswire

    Wave Life Sciences to Host Analyst and Investor Research Day on October 7, 2019

    CAMBRIDGE, Mass., Sept. 06, 2019 -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for.

  • GlobeNewswire

    Wave Life Sciences to Present at the Morgan Stanley Global Healthcare Conference

    CAMBRIDGE, Mass., Aug. 26, 2019 -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people.

  • GlobeNewswire

    Wave Life Sciences Appoints Mark Baldry as Chief Commercial Officer

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the appointment of Mark Baldry as Chief Commercial Officer. In this newly created position, Mr. Baldry will build and oversee Wave’s global commercial strategy and organization, including its sales, marketing and market access and reimbursement teams. Initially, he will focus on the launch planning for suvodirsen, the company’s investigational stereopure oligonucleotide intended for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.

  • Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates

    Wave Life Sciences (WVE) delivered earnings and revenue surprises of -16.19% and -51.61%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Wave Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update

    Interim efficacy data from ongoing suvodirsen open-label extension study on track for 4Q 2019 Phase 2/3 DYSTANCE 51 global, placebo-controlled study of suvodirsen initiated.

  • Is Wave Life Sciences Ltd. (NASDAQ:WVE) Overpaying Its CEO?
    Simply Wall St.

    Is Wave Life Sciences Ltd. (NASDAQ:WVE) Overpaying Its CEO?

    In 2013 Paul Bolno was appointed CEO of Wave Life Sciences Ltd. (NASDAQ:WVE). First, this article will compare CEO...

  • Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues
    Zacks

    Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues

    Sarepta's (SRPT) shares surge after safety issues are observed in Pfizer's early-stage clinical study related to its gene therapy for DMD.

  • GlobeNewswire

    Wave Life Sciences Announces Initiation of DYSTANCE 51, a Phase 2/3 Clinical Trial of Suvodirsen

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the initiation of DYSTANCE 51, the Phase 2/3 efficacy and safety clinical trial of suvodirsen, an investigational stereopure oligonucleotide intended for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. “The initiation of the DYSTANCE 51 Phase 2/3 study represents a significant milestone for Wave and our DMD clinical program, as well as an important development for the families affected by Duchenne,” said Michael Panzara, MD, MPH, Chief Medical Officer of Wave Life Sciences.

  • GlobeNewswire

    Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer

    Adaptimmune Therapeutics plc (ADAP) today announced that Adrian Rawcliffe, currently Chief Financial Officer (CFO) of the Company, will succeed James Noble as Chief Executive Officer (CEO). This transition will occur when James retires from his executive duties and transitions to a non-executive director role on the Company’s Board on September 1, 2019.

  • GlobeNewswire

    Wave Life Sciences to Present at Parent Project Muscular Dystrophy 2019 Annual Conference

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Michael Panzara, MD, MPH, Chief Medical Officer, will present at the Parent Project Muscular Dystrophy (PPMD) 2019 Annual Conference in Orlando, Fla. on Saturday, June 29, 2019 at 12:00 p.m. ET. The presentation will include an overview of the ongoing clinical development of suvodirsen, the company’s investigational stereopure oligonucleotide for boys with Duchenne muscular dystrophy who are amenable to exon 51 skipping. Suvodirsen is currently being studied in an open label extension (OLE) study, initiated in August 2018 with patients from the Phase 1 clinical trial.

  • Wave Life Sciences (WVE) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    Wave Life Sciences (WVE) Reports Q1 Loss, Misses Revenue Estimates

    Wave Life Sciences (WVE) delivered earnings and revenue surprises of -14.29% and -68.69%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    Wave Life Sciences: 1Q Earnings Snapshot

    The Singapore-based company said it had a loss of $1.36 per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...

  • GlobeNewswire

    Wave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update

    CAMBRIDGE, Mass., May 10, 2019 -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people.

  • Is WAVE Life Sciences Ltd. (WVE) A Good Stock To Buy ?
    Insider Monkey

    Is WAVE Life Sciences Ltd. (WVE) A Good Stock To Buy ?

    Is WAVE Life Sciences Ltd. (NASDAQ:WVE) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known […]

  • Wave Life Sciences (WVE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zacks

    Wave Life Sciences (WVE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • What Are Analysts Saying About Wave Life Sciences Ltd.'s (NASDAQ:WVE) Earnings Trajectory?
    Simply Wall St.

    What Are Analysts Saying About Wave Life Sciences Ltd.'s (NASDAQ:WVE) Earnings Trajectory?

    Wave Life Sciences Ltd.'s (NASDAQ:WVE) latest earnings announcement in December 2018 indicated that losses became smaller relative to the prior year's level - great news for investors...

  • Wave Life Sciences Plunges After DMD Study Data Readout
    Zacks

    Wave Life Sciences Plunges After DMD Study Data Readout

    Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.

  • Benzinga

    The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 16) Eidos Therapeutics Inc (NASDAQ: EIDX )(reported fourth ...

  • Associated Press

    Qualcomm and Progressive jump while Wave Life Sciences drops

    Stocks that moved substantially or traded heavily on Tuesday: Qualcomm Corp., up $13.27 to $70.45 The mobile chip maker settled a long-running financial dispute with iPhone maker Apple. Johnson & Johnson, ...

  • Benzinga

    Why Wave Life Sciences's Valuation Is Falling By 25%

    Small-cap biotech  Wave Life Sciences Ltd (NASDAQ: WVE ) — which fell  last week following a delay in the release of top-line data from its Huntington disease candidates — is once again under pressure ...

  • GlobeNewswire

    Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the final results from its Phase 1 clinical trial of investigational suvodirsen (WVE-210201) in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. The company also announced the design of its planned Phase 2/3 clinical trial of suvodirsen in DMD, DYSTANCE 51.